Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment - PubMed (original) (raw)
. 2013 Aug 1;73(15):4629-40.
doi: 10.1158/0008-5472.CAN-12-3058. Epub 2013 May 30.
Dominique Poujol, Amélien Sanlaville, Vanja Sisirak, Michael Gobert, Isabelle Durand, Bertrand Dubois, Isabelle Treilleux, Jacqueline Marvel, Jaromir Vlach, Jean-Yves Blay, Nathalie Bendriss-Vermare, Christophe Caux, Isabelle Puisieux, Nadège Goutagny
Affiliations
- PMID: 23722543
- DOI: 10.1158/0008-5472.CAN-12-3058
Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment
Isabelle Le Mercier et al. Cancer Res. 2013.
Abstract
Plasmacytoid dendritic cells (pDC) are key regulators of antiviral immunity. In previous studies, we reported that pDC-infiltrating human primary breast tumors represent an independent prognostic factor associated with poor outcome. To understand this negative impact of tumor-associated pDC (TApDC), we developed an orthotopic murine mammary tumor model that closely mimics the human pathology, including pDC and regulatory T cell (Treg) infiltration. We showed that TApDC are mostly immature and maintain their ability to internalize antigens in vivo and to activate CD4(+) T cells. Most importantly, TApDC were specifically altered for cytokine production in response to Toll-like receptor (TLR)-9 ligands in vitro while preserving unaltered response to TLR7 ligands (TLR7L). In vivo pDC depletion delayed tumor growth, showing that TApDC provide an immune-subversive environment, most likely through Treg activation, thus favoring tumor progression. However, in vivo intratumoral administration of TLR7L led to TApDC activation and displayed a potent curative effect. Depletion of pDC and type I IFN neutralization prevented TLR7L antitumoral effect. Our results establish a direct contribution of TApDC to primary breast tumor progression and rationalize the application of TLR7 ligands to restore TApDC activation in breast cancer. Cancer Res; 73(15); 4629-40. ©2013 AACR.
Similar articles
- Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression.
Sisirak V, Faget J, Gobert M, Goutagny N, Vey N, Treilleux I, Renaudineau S, Poyet G, Labidi-Galy SI, Goddard-Leon S, Durand I, Le Mercier I, Bajard A, Bachelot T, Puisieux A, Puisieux I, Blay JY, Ménétrier-Caux C, Caux C, Bendriss-Vermare N. Sisirak V, et al. Cancer Res. 2012 Oct 15;72(20):5188-97. doi: 10.1158/0008-5472.CAN-11-3468. Epub 2012 Jul 25. Cancer Res. 2012. PMID: 22836755 - Activation of dendritic cells via TLR7 reduces Foxp3 expression and suppressive function in induced Tregs.
Hackl D, Loschko J, Sparwasser T, Reindl W, Krug AB. Hackl D, et al. Eur J Immunol. 2011 May;41(5):1334-43. doi: 10.1002/eji.201041014. Eur J Immunol. 2011. PMID: 21469103 - Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells.
Sisirak V, Vey N, Goutagny N, Renaudineau S, Malfroy M, Thys S, Treilleux I, Labidi-Galy SI, Bachelot T, Dezutter-Dambuyant C, Ménétrier-Caux C, Blay JY, Caux C, Bendriss-Vermare N. Sisirak V, et al. Int J Cancer. 2013 Aug 1;133(3):771-8. doi: 10.1002/ijc.28072. Epub 2013 Mar 8. Int J Cancer. 2013. PMID: 23389942 - Tolerogenic plasmacytoid DC.
Matta BM, Castellaneta A, Thomson AW. Matta BM, et al. Eur J Immunol. 2010 Oct;40(10):2667-76. doi: 10.1002/eji.201040839. Eur J Immunol. 2010. PMID: 20821731 Free PMC article. Review.
Cited by
- Molecular understanding and clinical aspects of tumor-associated macrophages in the immunotherapy of renal cell carcinoma.
Liu H, Lv Z, Zhang G, Yan Z, Bai S, Dong D, Wang K. Liu H, et al. J Exp Clin Cancer Res. 2024 Aug 22;43(1):242. doi: 10.1186/s13046-024-03164-y. J Exp Clin Cancer Res. 2024. PMID: 39169402 Free PMC article. Review. - TLR7 agonist, DSP-0509, with radiation combination therapy enhances anti-tumor activity and modulates T cell dependent immune activation.
Ota Y, Inagaki R, Nagai Y, Hirose Y, Murata M, Yamamoto S. Ota Y, et al. BMC Immunol. 2024 Jul 25;25(1):48. doi: 10.1186/s12865-024-00643-x. BMC Immunol. 2024. PMID: 39054418 Free PMC article. - Toll-like receptors in breast cancer immunity and immunotherapy.
Zhou J, Zhang L, Liu S, DeRubeis D, Zhang D. Zhou J, et al. Front Immunol. 2024 Jun 6;15:1418025. doi: 10.3389/fimmu.2024.1418025. eCollection 2024. Front Immunol. 2024. PMID: 38903515 Free PMC article. Review. - Dendritic cell subsets and implications for cancer immunotherapy.
Chen MY, Zhang F, Goedegebuure SP, Gillanders WE. Chen MY, et al. Front Immunol. 2024 Jun 5;15:1393451. doi: 10.3389/fimmu.2024.1393451. eCollection 2024. Front Immunol. 2024. PMID: 38903502 Free PMC article. Review. - A combination of a TLR7/8 agonist and an epigenetic inhibitor suppresses triple-negative breast cancer through triggering anti-tumor immune.
Jiang Z, Cai G, Liu H, Liu L, Huang R, Nie X, Gui R, Li J, Ma J, Cao K, Luo Y. Jiang Z, et al. J Nanobiotechnology. 2024 May 29;22(1):296. doi: 10.1186/s12951-024-02525-1. J Nanobiotechnology. 2024. PMID: 38811964 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases
Research Materials